Angi also operates Handy, a platform for household services, primarily cleaning and repair services; Angi Roofing, which provides roof replacement and repair services; and home services marketplaces under the Travaux, MyHammer, Werkspot, MyBuilder and Instapro names.
Goldman Sachs has a $12 price target for Angi stock, while the consensus target is $11.59. The shares traded on Friday at $4.85. Hitting the Goldman Sachs target would be about a 128% gain.
Array Technologies
This company is still sometimes confused with a biotech with a similar name that Pfizer bought in 2019. Array Technologies Inc. (NASDAQ: ARRY) provides solar tracking solutions and services for utility-scale projects. Its products include DuraTrack HZ v3, a single-axis solar tracking system, and SmarTrack, a machine learning software that automatically adjusts module angles in response to weather and site conditions.
This stock had a red-hot initial public offering in 2020. Shares charged out of the gate, as the first trade was 34% above where the upsized IPO was priced. A total of 47.5 million shares were sold in the offering, as the maker of ground-mounting systems used in solar energy projects sold 7 million shares to raise $154 million and a selling shareholder sold 40.5 million shares.
Since then, Array Technologies stock has crashed and is offering investors an incredible entry point.
The Goldman Sachs target price is $21, and the consensus target for Array Technologies stock is $21.80. Shares traded on Friday at $7.60. Hitting the Goldman Sachs target would be a 148% gain or so.
Kinnate Biopharma
If clinical data goes the way the analysts expect, this stock could be an incredible home run. Kinnate Biopharma Inc. (NASDAQ: KNTE) is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States.
The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
The company recently announced that the first patient has commenced treatment in its Phase 1 KN-4802 clinical trial evaluating its lead fibroblast growth factor receptor (FGFR) product candidate, KIN-3248. This is a next-generation pan-FGFR inhibitor being developed for the treatment of intrahepatic cholangiocarcinoma and urothelial carcinoma, as well as other solid tumors.
The $44 Goldman Sachs price objective is higher than the also incredible $41.50 consensus target. The shares traded at $8.40 on Friday. Hitting the Goldman Sachs target would be a moonshot 415% gain.
Vivint Smart Home
This off-theadar company has been growing quickly, as home security has become a priority for many. Vivint Smart Home Inc. (NYSE: VVNT) engages in the sale, installation, servicing and monitoring of smart home and security systems, primarily in the United States and Canada.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
